KYTX
Income statement / Annual
Last year (2025), Kyverna Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Kyverna Therapeutics Inc.'s net income was -$161.31 M.
See Kyverna Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$7.03 M |
$5.66 M |
| Cost of Revenue |
$0.00
|
$2.13 M
|
$1.71 M
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$2.13 M
|
-$1.71 M
|
$7.03 M
|
$5.66 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$133.72 M
|
$112.47 M
|
$48.22 M
|
$28.40 M
|
$25.85 M
|
| General & Administrative Expenses |
$36.11 M
|
$30.13 M
|
$0.00
|
$8.01 M
|
$6.15 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$36.11 M
|
$30.13 M
|
$12.48 M
|
$8.01 M
|
$6.15 M
|
| Other Expenses |
$0.00
|
-$2.13 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$169.83 M
|
$140.47 M
|
$60.70 M
|
$36.41 M
|
$32.00 M
|
| Cost And Expenses |
$169.83 M
|
$142.60 M
|
$62.41 M
|
$36.41 M
|
$32.00 M
|
| Interest Income |
$9.09 M
|
$15.36 M
|
$2.28 M
|
$565.00 K
|
$1.00 K
|
| Interest Expense |
$489.00 K
|
$142.00 K
|
$187.00 K
|
$65.00 K
|
$3.00 K
|
| Depreciation & Amortization |
$1.80 M
|
$2.13 M
|
$1.71 M
|
$1.05 M
|
$586.00 K
|
| EBITDA |
-$159.02 M |
-$125.20 M |
-$58.47 M |
-$27.78 M |
-$25.76 M |
| EBITDA Ratio |
0
|
0
|
0
|
-3.95
|
-4.55
|
| Operating Income Ratio |
0
|
0
|
0
|
-4.18
|
-4.66
|
| Total Other Income/Expenses Net |
$8.52 M
|
$15.13 M
|
$2.04 M
|
$491.00 K
|
-$4.00 K
|
| Income Before Tax |
-$161.31 M
|
-$127.48 M
|
-$60.37 M
|
-$28.89 M
|
-$26.35 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-4.11
|
-4.66
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$161.31 M
|
-$127.48 M
|
-$60.37 M
|
-$28.89 M
|
-$26.35 M
|
| Net Income Ratio |
0
|
0
|
0
|
-4.11
|
-4.66
|
| EPS |
-3.64 |
-3.33 |
-0.0001 |
-1.12 |
-1.02 |
| EPS Diluted |
-3.64 |
-3.33 |
-0.0001 |
-1.12 |
-1.02 |
| Weighted Average Shares Out |
$44.26 M
|
$38.33 M
|
$673.62 M
|
$25.80 M
|
$25.80 M
|
| Weighted Average Shares Out Diluted |
$44.26 M
|
$38.33 M
|
$673.62 M
|
$25.80 M
|
$25.80 M
|
| Link |
|
|
|
|
|
